Document 0068
 DOCN  M9620068
 TI    Vortex keratopathy associated with atovaquone.
 DT    9602
 AU    Shah GK; Cantrill HL; Holland EJ; Department of Ophthalmology,
       University of Minnesota Hospital and; Clinics, USA.
 SO    Am J Ophthalmol. 1995 Nov;120(5):669-71. Unique Identifier : AIDSLINE
       MED/96065059
 AB    PURPOSE: We studied a case of vortex keratopathy that was associated
       with the use of atovaquone. METHOD: A patient with acquired
       immunodeficiency syndrome (AIDS) with pulmonary Pneumocystis carinii was
       treated with 750 mg of atovaquone three times a day. RESULTS: Similar to
       previous findings of drug-induced vortex keratopathy, atovaquone vortex
       keratopathy is presumably caused by its lipophilic properties. This
       property is similar to that of other lipophilic agents such as
       amiodarone, chloroquine, chlorpromazine, quinacrine, and suramin.
       CONCLUSION: Atovaquone should be added to the list of agents causing
       vortex keratopathy involving the corneal epithelium.
 DE    Antifungal Agents/*ADVERSE EFFECTS/THERAPEUTIC USE  AIDS-Related
       Opportunistic Infections/DRUG THERAPY  Case Report  Cornea/*DRUG
       EFFECTS/PATHOLOGY  Corneal Diseases/*CHEMICALLY INDUCED/PATHOLOGY
       Epithelium/DRUG EFFECTS/PATHOLOGY  Human  Male  Middle Age
       Naphthoquinones/*ADVERSE EFFECTS/THERAPEUTIC USE  Pneumonia,
       Pneumocystis carinii/DRUG THERAPY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).